Verrica Pharmaceuticals vs Viridian Therapeutics, Inc.\DE
VRCA and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VRCA and VRDN compare
Viridian Therapeutics, Inc.\DE is the larger company, worth 61 times as much as Verrica Pharmaceuticals ($3.4B against $55.0M).
Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus 106% for Verrica Pharmaceuticals).
Verrica Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −103% compared with −544% at Viridian Therapeutics, Inc.\DE.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VRCA | VRDN |
|---|---|---|
| Size and price | ||
| Market cap | $55.0M | $3.4B |
| Share price | $3.20 | $29.80 |
| Change, 1 year | −17.3% | 4.6% |
| Change, 5 years | −96.9% | 62.8% |
| Beta (5Y) | 5.05 | −0.12 |
| Employees | 76 | 252 |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× (better) | 47.5× |
| P/B | 12.8× | 5.1× (better) |
| FCF yield | – | −9.9% |
| Fair value | – | $8.47 |
| Margin of safety | – | −252% |
| Growth | ||
| Revenue growth (TTM) | 106% | 23220% (better) |
| Revenue growth, 5Y average | – | 132% |
| Profitability | ||
| Operating margin | −93.6% (better) | −570% |
| Net margin | −103% (better) | −544% |
| FCF margin | – | −471% |
| Return on equity | – | −65.7% |
| Financial health | ||
| Interest coverage | −7.6× (better) | −26.0× |
| Current ratio | 1.45 | 16.95 (better) |
| Altman Z-score | −13.90 | 2.61 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −1.7% |
| Shareholder yield | 0.00% (better) | −1.7% |
| Ownership | ||
| Held by institutions | 27.1% | 120% |
| Held by insiders | – | 21.8% |
| Insider net buying, 12 months | $211K | $19.6M (better) |
| Short interest, % of float | – | 19.2% |
Go deeper
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.